Charles River Laboratories International vs Exelixis
Charles River Laboratories International (CRL), health care, and Exelixis (EXEL), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Exelixis is worth $16.7B on the stock market and Charles River Laboratories International $15.9B: Exelixis is valued at 5% more. Charles River Laboratories International trades at 365 times earnings and Exelixis at 20.1; operating margins in their latest fiscal years were 0.63% and 37.6%. Over the past year Charles River Laboratories International's share price has moved +106% and Exelixis's +57.3%.
Key facts
- Charles River Laboratories International market value
- $15.9B
- Exelixis market value
- $16.7B
- Charles River Laboratories International P/E
- 365
- Exelixis P/E
- 20.1
- Charles River Laboratories International revenue
- $4BFY to 2025-12-27
- Exelixis revenue
- $2.3BFY to 2026-01-02
- Superinvestors holding both
- 0
Market values as of .
| Measure | Charles River Laboratories International | Exelixis |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-27 | 2026-01-02 |
| Size | ||
| Market cap | $15.9Blower | $16.7Bhigher |
| Revenue | $4Bhigher | $2.3Blower |
| Earnings | -$144.3Mlower | $782.6Mhigher |
| Employees | 18,300higher | 1,077lower |
| Total assets | $7.1Bhigher | $2.8Blower |
| Valuation | ||
| P/E | 365higher | 20.1lower |
| P/S | 4.0lower | 7.2higher |
| P/B | 4.9lower | 9.1higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 0.63%lower | 37.6%higher |
| Balance sheet | ||
| Net assets | $3.2Bhigher | $2.2Blower |
| Total liabilities | $3.9Bhigher | $683.1Mlower |
| Total debt | $2.1B | — |
| Cash on hand | $213.8Mlower | $482.5Mhigher |
| Price change | ||
| Today | -1.00%lower | +2.09%higher |
| 1 year | +106%higher | +57.3%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Charles River Laboratories International only (7)
- John Rogers3.7%
- Anthony Bozza0.9%
- Bill Nygren0.7%
- Karthik Sarma0.5%
- Joel Greenblatt0.2%
- Ken Griffin0.2%
- Murray Stahl<0.1%
Exelixis only (5)
Percentages are each holding's share of that investor's reported portfolio. Who owns CRL · Who owns EXEL
More on Charles River Laboratories International
- Charles River Laboratories International (CRL) stock page
- Charles River Laboratories International market cap
- Charles River Laboratories International revenue
- Charles River Laboratories International P/E ratio
- Charles River Laboratories International operating margin
- Charles River Laboratories International total debt
- Largest health care companies
Further comparisons
Charles River Laboratories International against its closest peers
Exelixis against its closest peers
Learn
Questions and answers
Which is bigger, Charles River Laboratories International or Exelixis?
By market value, Exelixis is the larger: $16.7B against $15.9B for Charles River Laboratories International. By revenue in its latest fiscal year, Charles River Laboratories International is the larger: $4B against $2.3B for Exelixis.
Which has the higher P/E ratio?
Charles River Laboratories International: 365, against 20.1 for Exelixis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Exelixis: 37.6%, against 0.63% for Charles River Laboratories International. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Charles River Laboratories International and Exelixis?
None of the tracked superinvestors holds both in their latest 13F filing. 7 hold Charles River Laboratories International and 5 hold Exelixis.
Cite this page
Funkfolio, “Charles River Laboratories International vs Exelixis”, data as of 18 November 2026. https://funkfolio.com/compare/crl-vs-exel
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.